Opinion|Videos|September 3, 2024
Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
Medical experts offer insights on the COMMANDS trial findings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the expanded indication of luspatercept in lower-risk myelodysplastic syndromes (based on the COMMANDS trial findings) and its implications for clinical practice.
Advertisement
Related to this article
The 2026 meeting in Denver features more than 265 hours of programming, real-world MASH treatment data, and late-breaking results in rare liver diseases.
In 299 patients, more involved compartments were linked to higher complication risk after one-stage resection; 14.4% had documented recurrence.
A cranberry supplement was tied to greater OAB symptom score reductions than placebo in a 25-woman pilot trial, but urobiome findings were unconfirmed.
In a matched analysis of Epic COSMOS records, acoramidis was tied to an 18% lower composite risk and about 25% lower hospitalization risk.
A runner's death at the NYC marathon highlights how heat, dehydration, illness, drugs, and genetics can raise exertional rhabdomyolysis risk.
Naim Alkhouri, MD, on when to judge MASH treatment response, counseling on weight and muscle loss, primary care screening, and future trial end points.
In an insured population with advanced lung cancer, clinical trial participants had lower or similar total health care costs compared with nonparticipants.
ALLEGRO extension news shows Litfulo (ritlecitinib) delivers durable hair regrowth in severe alopecia areata after 3 years.
Advertisement
Advertisement
Trending on AJMC
1
NYC Marathon Death Puts Rhabdomyolysis Risk Factors in Focus
2
Real-World Evidence, Rare Liver Disease Data Headline Kidney Week 2026
3
Cranberry Supplement Tied to Greater OAB Score Reductions in Pilot Trial
4
Disease Extent Linked to Complications After Deep Endometriosis Surgery
5